


Terutroban

Cat. No.:	HY-16991		
CAS No.:	165538-40-9		
Molecular Formula:	C ₂₀ H ₂₂ ClNO ₄ S		
Molecular Weight:	407.91		
Target:	Prostaglandin Receptor		
Pathway:	GPCR/G Protein		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (245.15 mM; Need ultrasonic)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	2.4515 mL	12.2576 mL	24.5152 mL
5 mM	0.4903 mL	2.4515 mL	4.9030 mL
10 mM	0.2452 mL	1.2258 mL	2.4515 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.5 mg/mL (6.13 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (6.13 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Terutroban is a thromboxane-prostaglandin receptor antagonist.

CUSTOMER VALIDATION

- Med Sci Monit. 2020 Jun 18;26:e923163.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. De La Cruz JP, et al. Effects of terutroban, a thromboxane/prostaglandin endoperoxide receptor antagonist, on retinal vascularity in diabetic rats. *Diabetes Metab Res Rev.* 2012 Feb;28(2):132-138.
- [2]. Bots ML, et al. Thromboxane prostaglandin receptor antagonist and carotid atherosclerosis progression in patients with cerebrovascular disease of ischemic origin: a randomized controlled trial. *Stroke.* 2014 Aug;45(8):2348-2353.
- [3]. Lesault PF, et al. Daily administration of the TP receptor antagonist terutroban improved endothelial function in high-cardiovascular-risk patients with atherosclerosis. *Br J Clin Pharmacol.* 2011 Jun;71(6):844-851.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA